drugset / Trial / NCT05039801
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To find the highest tolerable dose of IACS-6274 that can be given alone, in combination with bevacizumab and paclitaxel, or in combination with capivasertib to patients who have solid tumors. The safety and tolerability of the study drug(s) will also be studied.
Timeline
- Start
- 2021-09-30
- Primary completion
- 2028-03-30
- Completion
- 2028-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Subject | Capivasertib | Small molecule | — | Oral |
| Subject | IPN60090 | Small molecule | — | Oral |
| Subject | Paclitaxel | Small molecule | — | Intravenous |